BELKIS LORENZO GIMENO: Open Payments
NPI 1770073421 · GARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$314 in 17 payments from 6 companies in 2025. Trend: 2023 $227 · 2024 $665 · 2025 $314
Food & beverage: $314
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 10 | $182 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $49 |
| Lilly USA, LLC | 1 | $24 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| Novo Nordisk Inc | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: REPATHA, OTEZLA, JARDIANCE, MOUNJARO, Natroba, Ozempic, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
